Applying Spectral Shift technology to study IDPs: Direct binding and displacement assays of MYC:MAX inhibitors

December 15, 2023

MYC is an important therapeutic target that associates with MAX to regulate gene transcription. Its lack of binding pockets and the presence of disordered regions make it a difficult protein to study with biophysical tools that require immobilization during drug discovery and development.

For this case study we used Dianthus with Spectral Shift technology to evaluate the direct binding of three MYC:MAX inhibitors, and their ability to displace DNA. The immobilization-free, in-solution, and fluorescence-based method made it possible to easily study interactions involving a protein with intrinsically disordered regions like MYC.

Previous Video
The use of Spectral Shift in identifying Microcycle® hits for challenging therapeutic targets
The use of Spectral Shift in identifying Microcycle® hits for challenging therapeutic targets

Transcription factors have traditionally been considered challenging therapeutic targets. Their intrinsic d...

Up next
Conversation:  How Aaron Frimel from Thermo Fisher Scientific approaches biologics formulation
Conversation: How Aaron Frimel from Thermo Fisher Scientific approaches biologics formulation

Join this conversation to gain insight into how the Analytical and Formulation Sciences team at Thermo Fish...